luliconazole

Increased benzodiazepine levels, increased sedation and respiratory depression

Monitor for increased sedation. Adjust benzodiazepine dose as needed, or consider a benzodiazepine not primarily metabolized by CYP3A4 (e.g., lorazepam).

Increased calcium channel blocker levels, increased risk of hypotension, bradycardia, and peripheral edema

Monitor blood pressure and heart rate. Adjust calcium channel blocker dose as needed.

Increased systemic corticosteroid exposure, increased risk of Cushing's syndrome and adrenal suppression

Monitor for signs of systemic corticosteroid effects. Consider reducing corticosteroid dose or using an alternative.

Increased cyclosporine levels, increased risk of nephrotoxicity and other cyclosporine-related adverse effects

Monitor cyclosporine levels if co-administered. Adjust cyclosporine dose as needed.

Increased phenytoin levels, increased risk of phenytoin toxicity (e.g., nystagmus, ataxia)

Monitor phenytoin levels if co-administered. Adjust phenytoin dose as needed.

Increased statin levels, increased risk of myopathy and rhabdomyolysis

Consider using a statin not primarily metabolized by CYP3A4 (e.g., pravastatin, rosuvastatin) or reduce statin dose. Monitor for muscle pain.

Increased sulfonylurea levels, increased risk of hypoglycemia

Monitor blood glucose closely if co-administered. Adjust sulfonylurea dose as needed.

Increased tacrolimus levels, increased risk of nephrotoxicity and other tacrolimus-related adverse effects

Monitor tacrolimus levels if co-administered. Adjust tacrolimus dose as needed.

Increased INR, increased bleeding risk

Monitor INR closely if co-administered. Adjust warfarin dose as needed.

Increased digoxin levels, increased risk of digoxin toxicity

Monitor digoxin levels if co-administered. Adjust digoxin dose as needed.